Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Blood Cancer ; 63(3): 554-7, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26513138

ABSTRACT

The risk of developing skin cancer is elevated among childhood cancer survivors (CCS), particularly among those treated with radiation. This survey study examined the skin cancer surveillance behaviors of 94 CCS. Approximately 48% of CCS had ever conducted skin self-examination (SSE) and 31% had ever received a physician skin examination. Rates of physician skin examination were 2.5 times higher among CCS treated with radiation compared to those without radiation. However, rates of SSEs did not differ based on treatment history. These findings highlight the need to promote skin cancer surveillance as an important aspect of CCS survivorship care.


Subject(s)
Self-Examination , Skin Neoplasms/diagnosis , Skin Neoplasms/psychology , Adult , Female , Humans , Male , Physicians , Skin Neoplasms/radiotherapy
2.
Toxicol Sci ; 122(1): 170-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21507990

ABSTRACT

Certolizumab pegol (CZP) is a PEGylated Fab' fragment of a humanized monoclonal immunoglobulin G (IgG)1 antibody that binds to human tumor necrosis factor alpha (TNFα) with high affinity. As for many monoclonal antibodies (mAbs), nonclinical safety assessment of CZP has been constrained because of its limited species cross-reactivity and recognition of only nonhuman primate and human TNFα, which presents particular challenges for assessing reproductive and developmental safety. To comprehensively assess the potential liability of TNFα suppression on reproductive and developmental processes, a PEGylated Fab' anti-rat TNFα antibody surrogate (cTN3 PF) has been developed and evaluated for reproductive toxicity. Conventional rat fertility and early embryonic development, embryo-fetal toxicity and pre- and postnatal development studies have been shown to be free of maternal, reproductive, or development toxicity effects, following sustained TNFα inhibition with cTN3 PF. Importantly, these studies have also shown that in marked contrast to a whole IgG anti-TNFα antibody, the PEGylated Fab' antibody cTN3 PF homologous to certolizumab pegol demonstrated negligible fetal exposure following maternal administration during the period of organogenesis. In addition to minimal placental transmission, transfer to milk was lower and fetal absorption negligible compared with the whole IgG antibody cTN3 γ1, resulting in little or no detectable antibody in the plasma of lactating pups.


Subject(s)
Antibodies, Monoclonal, Humanized/toxicity , Immunoglobulin Fab Fragments/toxicity , Polyethylene Glycols/toxicity , Tumor Necrosis Factor-alpha/metabolism , Animals , Certolizumab Pegol , Female , Immunoglobulin G/toxicity , Male , Pregnancy , Rats , Rats, Sprague-Dawley
3.
MAbs ; 2(2): 137-47, 2010.
Article in English | MEDLINE | ID: mdl-20190560

ABSTRACT

Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Crohn Disease/drug therapy , Immunoglobulin Fab Fragments/therapeutic use , Immunotherapy , Polyethylene Glycols/therapeutic use , Antibodies, Monoclonal, Humanized , Arthritis, Rheumatoid/immunology , Canada , Certolizumab Pegol , Clinical Trials as Topic , Crohn Disease/immunology , Drug Approval , European Union , Humans , Immunoglobulin Fab Fragments/pharmacology , Immunotherapy/economics , Immunotherapy/trends , Marketing , Polyethylene Glycols/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , United States
4.
Inflamm Bowel Dis ; 13(11): 1323-32, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17636564

ABSTRACT

BACKGROUND: Inhibitors of tumor necrosis factor alpha (TNFalpha) have demonstrated significant efficacy in chronic inflammatory diseases, including Crohn's disease (CD). To further elucidate the mechanisms of action of these agents, we compared the anti-TNFalpha agents certolizumab pegol, infliximab, adalimumab, and etanercept in several in vitro systems. METHODS: The ability of each anti-TNFalpha agent to neutralize soluble and membrane-bound TNFalpha; mediate cytotoxicity, affect apoptosis of activated human peripheral blood lymphocytes and monocytes; induce degranulation of human peripheral blood granulocytes, and modulate lipopolysaccharide (LPS)-induced interleukin (IL)-1beta production by human monocytes was measured in vitro. RESULTS: All 4 agents neutralized soluble TNFalpha and bound to and neutralized membrane TNFalpha. Infliximab and adalimumab were comparable in their ability to mediate complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and to increase the proportion of cells undergoing apoptosis and the level of granulocyte degranulation. Etanercept generally mediated these effects to a lesser degree, while certolizumab pegol gave similar results to the control reagents. LPS-induced IL-1beta production was inhibited by certolizumab pegol, infliximab, and adalimumab, but only partially inhibited by etanercept. CONCLUSIONS: In contrast to the other anti-TNFalpha agents tested, certolizumab pegol did not mediate increased levels of apoptosis in any of the in vitro assays used, suggesting that these mechanisms are not essential for the efficacy of anti-TNFalpha agents in CD. As certolizumab pegol, infliximab, and adalimumab, but not etanercept, almost completely inhibited LPS-induced IL-1beta release from monocytes, inhibition of cytokine production may be important for efficacy of anti-TNFalpha agents in CD.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Immunoglobulin Fab Fragments/pharmacology , Polyethylene Glycols/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Apoptosis/drug effects , Blood Cells , Cells, Cultured , Certolizumab Pegol , Drug Evaluation , Etanercept , Granulocytes/drug effects , Humans , Immunoglobulin G/pharmacology , Inflammatory Bowel Diseases/drug therapy , Infliximab , Interleukin-1beta/biosynthesis , Lipopolysaccharides/pharmacology , Lymphocytes/cytology , Lymphocytes/drug effects , Monocytes , Receptors, Tumor Necrosis Factor
5.
Cancer Immunol Immunother ; 54(1): 11-24, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15693135

ABSTRACT

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin is a clinically validated strategy in cancer therapy. This study describes the selection of a murine anti-CD22 mAb, m5/44, as a targeting agent, its conjugation to a derivative of calicheamicin (CalichDM) via either acid-labile or acid-stable linkers, the antitumor activity of CalichDM conjugated to m5/44, and its subsequent humanization by CDR grafting. Murine IgG1 mAb m5/44 was selected based on its subnanomolar affinity for CD22 and ability to be internalized into B cells. CalichDM conjugated to m5/44 caused potent growth inhibition of CD22+ human B-cell lymphomas (BCLs) in vitro. The conjugate of m5/44 with an acid-labile linker was more potent than an acid-stable conjugate, a nonbinding conjugate with a similar acid-labile linker, or unconjugated CalichDMH in inhibiting BCL growth. CalichDM conjugated to m5/44 caused regression of established BCL xenografts in nude mice. In contrast, both unconjugated m5/44 and a nonbinding conjugate were ineffective against these xenografts. Based on the potent antitumor activity of m5/44-CalichDM conjugates, m5/44 was humanized by CDR grafting to create g5/44, an IgG4 anti-CD22 antibody. Both m5/44 and g5/44 bound CD22 with subnanomolar affinity. Competitive blocking with previously characterized murine anti-CD22 mAbs suggested that g5/44 recognizes epitope A located within the first N-terminal Ig-like domain of human CD22. Antitumor efficacy of CalichDM conjugated to g5/44 against BCL xenografts was more potent than its murine counterpart. Based on these results, a calicheamicin conjugate of g5/44, CMC-544, was selected for further development as a targeted chemotherapeutic agent for the treatment of B-cell malignancies.


Subject(s)
Aminoglycosides/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antigens, CD/immunology , Antigens, Differentiation, B-Lymphocyte/immunology , Antineoplastic Agents/therapeutic use , Cell Adhesion Molecules/immunology , Immunoconjugates/therapeutic use , Lectins/immunology , Lymphoma, B-Cell/therapy , Amino Acid Sequence , Aminoglycosides/chemistry , Aminoglycosides/immunology , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Antineoplastic Agents/immunology , Binding, Competitive , Cell Line, Tumor , Epitopes/immunology , Female , Humans , Immunoconjugates/immunology , Lymphoma, B-Cell/immunology , Mice , Mice, Inbred BALB C , Mice, Nude , Molecular Sequence Data , Sialic Acid Binding Ig-like Lectin 2 , Xenograft Model Antitumor Assays/methods
6.
Blood ; 103(5): 1807-14, 2004 Mar 01.
Article in English | MEDLINE | ID: mdl-14615373

ABSTRACT

Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma-calicheamicin dimethyl hydrazide [CalichDMH], a potent DNA-binding cytotoxic antitumor antibiotic) is a clinically validated therapeutic option for patients with acute myeloid leukemia (AML). Here, we describe the preclinical profile of another immunoconjugate of CalichDMH, CMC-544, targeted to CD22 expressed by B-lymphoid malignancies. CMC-544 comprises a humanized IgG4 anti-CD22 monoclonal antibody (mAb), G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker. Both CMC-544 and unconjugated G5/44 bound human CD22 with subnanomolar affinity. CMC-544, but not unconjugated G5/44, exerted potent cytotoxicity against CD22+ B-cell lymphoma (BCL) cell lines (inhibitory concentration of 50%: 6-600 pM CalichDMH). CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10). CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass). In contrast, unconjugated CalichDMH, unconjugated G5/44, and an isotype-matched control conjugate, CMA-676, were ineffective against these BCL xenografts. Thus, CD22-targeted delivery of CalichDMH is a potent and effective preclinical therapeutic strategy for BCLs. The strong antitumor profile of CMC-544 supports its clinical evaluation as a treatment option for B-lymphoid malignancies.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD/biosynthesis , Antigens, Differentiation, B-Lymphocyte/biosynthesis , Cell Adhesion Molecules , Immunoconjugates/therapeutic use , Lectins/biosynthesis , Lymphoma, B-Cell/therapy , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal, Humanized , Antigens, CD/metabolism , Antigens, Differentiation, B-Lymphocyte/metabolism , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Female , Humans , Immunoglobulin G/metabolism , Immunotherapy/methods , Inhibitory Concentration 50 , Inotuzumab Ozogamicin , Lectins/metabolism , Lymphoma, B-Cell/metabolism , Lymphoma, Non-Hodgkin/metabolism , Mice , Mice, Inbred BALB C , Mice, Nude , Models, Chemical , Neoplasm Transplantation , Protein Binding , Sialic Acid Binding Ig-like Lectin 2 , Time Factors
7.
Immunology ; 110(1): 48-57, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12941140

ABSTRACT

Two phenotypically distinct subpopulations of dendritic cells (SIRPalpha+ CC81Ag- DC and SIRPalpha- CC81Ag+ DC) have previously been identified in bovine afferent lymph which show functional differences when assayed in vitro. The purpose of this study was to investigate whether differences in cytokine production between the two subpopulations might occur which could influence the bias of the immune response they stimulate. Qualitative and quantitative polymerase chain reactions were used to detect specific mRNA transcripts and flow cytometry and enzyme-linked immunosorbent assays were used to detect protein production. The SIRPalpha- CC81Ag+ DC produced considerably more interleukin-12 (IL-12) mRNA transcripts and protein than the SIRPalpha+ CC81Ag- DC. Conversely, SIRPalpha+ CC81Ag- DC contained more of both transcripts and protein for IL-1 and of transcripts for IL-6. A small percentage of both subpopulations produced interferon-gamma (IFN-gamma) as evidenced by cytoplasmic staining. Stimulation of DC by culture with CD40L+ cells increased the production of IL-1, IL-6 and IL-12 but quantitative differences between the subpopulations remained. Production of IL-10 was also evident following culture with CD40L+ cells or lipopolysaccharide primarily by the SIRPalpha+ CC81Ag- DC. No evidence was found for type 1 IFN production, and hence plasmacytoid DC, by DC in afferent lymph; both subpopulations appear to be myeloid in origin. These different cytokine repertoires of the two subpopulations of ex vivo DC isolated from afferent lymph imply functional differences that could influence the presentation of antigen to T cells and bias of the immune response following vaccination or infection.


Subject(s)
Cattle/immunology , Cytokines/biosynthesis , Dendritic Cells/immunology , Lymph/immunology , Animals , Cells, Cultured , Cytokines/genetics , Enzyme-Linked Immunosorbent Assay/methods , Flow Cytometry/methods , Immunophenotyping , Interferon Type I/biosynthesis , Polymerase Chain Reaction/methods , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...